NCT05170919
Comparing Olanzapine and Mirtazapine in the Improvement of Unintentional Weight Loss for Patients with Advanced Stage Cancer
Enrolling by Invitation
PHASE2Ages 18+InterventionalTreatmentEnglewood Hospital and Medical CenterInvestigator-initiated
~170 participants
Updated 2024-09-19 on ClinicalTrials.gov
What's tested:MirtazapineOlanzapine
At a glance
Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Weight
Measured over 6 months
Conditions
Where it's being run
1 sites across 1 statesNew Jersey1
Who to contact
This trial hasn't published a contact. View it on ClinicalTrials.gov
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Eligibility criteria
Inclusion
• 18 years of age or older
Able to provide informed consent
Pathologically and/or clinically confirmed diagnosis of advanced cancer
At any point of treatment with standard chemotherapy\*
Greater than or equal to 5% unintentional weight loss over the previous 3-6 months, not explained by simple starvation
Life expectancy of at least 4 months
Able to communicate well and comply with study requirements, including by phone and written logs
Patients on Dexamethasone will be allowed
Exclusion
• Abnormal liver function defined as \> twice upper limit of normal
Elevated QTc
Total parental nutrition (TPN) or enteral feeds (PEG/PEJ) for \>70% of their primary source of daily calorie intake
Taking Marinol within 2 week of enrollment onto study
What this trial measures
- Weight6 months
Patients will have their weight measured every month. A ratio of 5% weight gain or weight stabilization over time will be used to determine if the medication is making an impact.